SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GUMM - Eliminate the Common Cold
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Hank who wrote (2422)3/30/2000 3:39:00 AM
From: DanZ  Read Replies (1) of 5582
 
That's an interesting story, Hank, but I don't see the parallel to Gum Tech. You continue to refer to this company as if it is a "one product wonder". In reality, Gum Tech has a core gum business and at least two major new gum products on the way (nicotine gum and dental gum). Gum Tech also owns 60% of Gel Tech, which holds the intellectual property rights to Zicam. The company implied that they are working on an allergy product when they told shareholders about a clinical study for allergies. They also said that they plan to use the delivery system in Zicam to produce other products. You can fantasize that Gum Tech is a one product company, but eventually the market will discount the other products that they are working on and the stock will trade significantly higher.

There's no doubt that the market's myopia on Zicam has contributed to the decline in the stock. I sense that fear has a grip over the stock right now, and margin has probably exacerbated the effect. I believe that some investors have sold stock either out of fear for the unknown, to preserve their equity, or because they received a margin call that they can't or don't want to meet. Neither of these factors has anything to do with the fundamentals of the company and the stock will eventually turn around. Shorts can stomp up and down and claim that they were right because the stock is down. That is BS, and it will turn around when investors discount a fairer value for Zicam and other products.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News